SCHEMBL2368094

SCHEMBL2368094

COc1cc(S(=O)(=O)Cl)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 4/20 0.49
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA12 O43570 2/20 0.49
ACHE P22303 1/20 0.48
MAPT P10636 2/20 0.46
CYP3A4 P08684 1/20 0.46
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
CA4 P22748 1/20 0.45
CA7 P43166 1/20 0.45
EGFR P00533 1/20 0.45
TRPV4 Q9HBA0 1/20 0.44
PTGS2 P35354 1/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HTR1A P08908 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494498 0.86 CA9 (0.40) CA9CA1CA2CA12ACHE
SCHEMBL10565520 0.82 KDM4E (0.46) MAPTMAPK1ALDH1A1KDM4EHTR1A
SCHEMBL12626309 0.82 MAPT (0.42) CA9CA1CA2CA12MAPT
SCHEMBL5095441 0.82 POLB (0.59) CA9CA1CA2CA12ACHE
SCHEMBL31511125 0.81 TSHR (0.44) MAPTPOLBTSHRMAPK1TRPV4
SCHEMBL7319937 0.80 SMN1; SMN2 (0.52) CA9CA1CA2CA12ACHE
SCHEMBL7319931 0.78 CA9 (0.49) CA9CA1CA2CA12ACHE
SCHEMBL2217165 0.78 CYP3A4 (0.52) CA9CA1CA2CA12ACHE
SCHEMBL5212407 0.78 ALDH1A1 (0.38) CA9CA1CA2CA12ACHE
SCHEMBL14120915 0.78 PTGS2 (0.44) CA9CA1CA2MAPTTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212613-B1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL SCIENT IND RES (IN) 2020-12-16 EP disclosed
US-10246411-B2 (Z)-3,4,5-trimethoxystyrylbenzenesulfonamides as potential anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-04-02 US disclosed
US-20170327462-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-11-16 US disclosed
US-20170327462-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-11-16 US disclosed
EP-2488177-B1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS INC (US) 2016-10-12 EP disclosed
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC BURNS BARBIER LINDSAY (US) 2016-09-01 US disclosed
US-9340558-B2 Filamin a binding anti-inflammatory and analgesic PAIN THERAPEUTICS INC. (US) 2016-05-17 US disclosed
WO-2016067311-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-05-06 WO disclosed
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 EP disclosed
EP-2918587-A2 Filamin a binding anti-inflammatory and analgesic Pain Therapeutics, Inc. (US) 2015-09-16 EP disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5389630-A Diamine compound and brain protecting agent containing the same KOWA CO., LTD. (JP) 1995-02-14 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
EP-0541798-A1 NEW DIAMINE COMPOUND AND BRAIN PROTECTING AGENT CONTAINING THE SAME Kowa Company Ltd. (JP) 1993-05-19 EP disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed
US-4257952-A PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES STERLING DRUG INC. (US) 1981-03-24 US disclosed
US-4172834-A ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS STERLING DRUG INC. (US) 1979-10-30 US disclosed
US-4062864-A ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1977-12-13 US disclosed
US-3959309-A ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 CA9 4261/4885CA1 4454/4885CA2 3299/4885
US-10246411-B2 (Z)-3,4,5-trimethoxystyrylbenzenesulfonamides as potential anticancer agents BCL3, CASP3, HCCS CA9 98/4885CA1 1312/4885CA2 1347/4885
US-20170327462-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS BCL3, CASP3, HCCS CA9 202/4885CA1 2478/4885CA2 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.